Discovery on Target 2026 has ended. This guide stays up as the record of who was there. Next: Discovery on Target 2027, Oct 18–21, 2027 in Boston
Radioligand therapies at Discovery on Target 2026
Sep 28 – Oct 1, 2026 Boston, MA ~1.1k attendees Website
28 organizations at Discovery on Target 2026 present work in radioligand therapies: 21 drug developers, 4 academic, government and non-profit bodies and 3 technology and service providers. Between them they bring 62 presentations to the program. Most represented: AstraZeneca, University of California, San Francisco and Novartis. As of Oct 8, 2026.
| Organization | Discovery on Target 2026 Attendance |
|---|---|
AstraZeneca Cambridge, UK | |
Global biopharmaceutical company with medicines in oncology, cardiovascular, respiratory, immunology and rare diseases. | Chair Mon Sep 28 1:30pm–1:35pm Panel Tue Sep 29 11:05am–12:05pm Talk Tue Sep 29 1:50pm–2:20pm Talk Tue Sep 29 2:50pm–3:20pm Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Novel drug modalitiesInnovative discovery technologies Talk Wed Sep 30 9:05am–9:35am Talk Wed Sep 30 2:05pm–2:35pm Panel Wed Sep 30 3:05pm–4:05pm Panel Thu Oct 1 7:30am–8:15am |
University of California, San Francisco San Francisco, CA | |
Panel Mon Sep 28 5:00pm–6:00pm Talk Tue Sep 29 10:35am–11:35am Talk Tue Sep 29 11:35am–12:05pm Talk Wed Sep 30 11:50am–12:20pm Talk Wed Sep 30 12:20pm–12:50pm Talk Thu Oct 1 10:05am–10:35am Talk Thu Oct 1 10:35am–11:05am | |
Novartis Basel, Switzerland | |
Global pharmaceutical company; Novartis Biomedical Research is its drug discovery arm. | Panel Mon Sep 28 10:45am–11:30am Talk Tue Sep 29 2:20pm–2:50pm Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Novel drug modalitiesInnovative discovery technologies Talk Wed Sep 30 2:05pm–2:35pm Panel Thu Oct 1 7:30am–8:15am |
Perceptive Burlington, MA | |
Provides preclinical imaging, radiochemistry and radioligand assays, plus clinical trial imaging and trial-supply technology. | Chair Wed Sep 30 9:00am–9:05am Talk Wed Sep 30 11:50am–12:20pm Chair Wed Sep 30 2:00pm–2:05pm Panel Wed Sep 30 3:05pm–4:05pm |
University of Wisconsin–Madison Madison, WI | |
Talk Wed Sep 30 12:20pm–12:50pm Chair Thu Oct 1 9:00am–9:05am Talk Thu Oct 1 9:05am–9:35am Chair Thu Oct 1 3:30pm–3:35pm | |
Radioligand therapy developer for cancer, acquired by Novartis in 2024. | Talk Tue Sep 29 8:35am–9:05am Panel Wed Sep 30 3:05pm–4:05pm |
Non-profit working to widen patient access to targeted radionuclide therapy through education, advocacy and treatment donation programmes. | Panel Wed Sep 30 7:30am–8:15am |
Normunity New Haven, Connecticut | |
Chair Tue Sep 29 8:30am–8:35am Panel Tue Sep 29 11:05am–12:05pm Chair Tue Sep 29 1:45pm–1:50pm Talk Tue Sep 29 3:35pm–3:50pm | |
Actithera Cambridge, MA | |
Radiopharmaceutical company designing targeted molecules that carry radioactive isotopes to tumors. | Talk Tue Sep 29 10:35am–11:05am Panel Tue Sep 29 11:05am–12:05pm |
Panel Tue Sep 29 11:05am–12:05pm Talk Wed Sep 30 9:05am–9:35am |
Instantly find 20 buyers in radioligand therapies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse Discovery on Target 2026 by
Not affiliated with or endorsed by Discovery on Target or its organizers. Submit a correction